Daunorubicin accumulation by human myeloblasts varying in anthracycline resistance. 1984

D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn

Circulating myeloblasts were obtained from patients with acute myelogenous leukemias varying widely in anthracycline responsiveness. Studies were carried out in vitro to assess the capacity of such cells for daunorubicin accumulation. There was no correlation between drug responsiveness patterns in vivo vs. drug transport phenomena measured in vitro. A mode of enhanced anthracycline exodus demonstrable in certain drug-resistant murine leukemia cell lines could not be detected in the drug-resistant human myeloblasts.

UI MeSH Term Description Entries
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D009279 Naphthacenes Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Tetracenes,Benz(b)Anthracenes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
October 1985, European journal of cancer & clinical oncology,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
March 1992, Journal of bacteriology,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
February 2016, Toxicology and applied pharmacology,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
December 1998, British journal of cancer,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
December 1999, Haematologica,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
January 1989, Leukemia research,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
February 2000, European journal of cancer (Oxford, England : 1990),
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
January 1981, Cancer treatment reports,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
July 1997, Leukemia,
D Kessel, and C Wilberding, and C Karanes, and V Ratanatharathorn
September 2007, Cancer letters,
Copied contents to your clipboard!